Tags

Type your tag names separated by a space and hit enter

Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial.
Blood. 2004 Nov 15; 104(10):3028-37.Blood

Abstract

Various transplantation strategies have been designed to improve the poor prognosis of adult (ages 15 to 60 years) acute lymphoblastic leukemia (ALL). The GOELAL02 trial evaluated the impact of early allogeneic bone marrow transplantation (alloBMT) or delayed unpurged autologous stem cell transplantation (ASCT) for patients who had no human leukocyte antigen (HLA)-matched sibling donor or who were older than 50 years. Inclusion criteria included at least one of the following: age older than 35 years; non-T-ALL; leukocytosis greater than 30 x 10(9)/L; t(9;22), t(4;11), or t(1; 19); or failure to achieve complete remission (CR) after one induction course. Among 198 patients, the median age was 33 years. The CR rate was 80% with vincristine, idarubicine, L-asparaginase, and randomized intravenous injection or oral steroids (P = nonsignificant [ns]). AlloBMT was performed after 2 consolidation courses while ASCT was delayed after 1 additional reinduction. Intensified conditioning regimen before transplantation included etoposide, cyclophosphamide, and total body irradiation (TBI). Median follow-up was 5.1 years. The median overall survival (OS) was 29 months, with a 6-year OS of 41%. On an intent-to-treat analysis for patients younger than 50 years, alloBMT significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). Randomized interferon-alpha maintenance had no effect on relapse or survival after ASCT. In conclusion, the outcome of adult ALL is better after early alloBMT than after delayed ASCT.

Authors+Show Affiliations

Hematology Department, University of Angers, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15256423

Citation

Hunault, Mathilde, et al. "Better Outcome of Adult Acute Lymphoblastic Leukemia After Early Genoidentical Allogeneic Bone Marrow Transplantation (BMT) Than After Late High-dose Therapy and Autologous BMT: a GOELAMS Trial." Blood, vol. 104, no. 10, 2004, pp. 3028-37.
Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104(10):3028-37.
Hunault, M., Harousseau, J. L., Delain, M., Truchan-Graczyk, M., Cahn, J. Y., Witz, F., Lamy, T., Pignon, B., Jouet, J. P., Garidi, R., Caillot, D., Berthou, C., Guyotat, D., Sadoun, A., Sotto, J. J., Lioure, B., Casassus, P., Solal-Celigny, P., Stalnikiewicz, L., ... Ifrah, N. (2004). Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood, 104(10), 3028-37.
Hunault M, et al. Better Outcome of Adult Acute Lymphoblastic Leukemia After Early Genoidentical Allogeneic Bone Marrow Transplantation (BMT) Than After Late High-dose Therapy and Autologous BMT: a GOELAMS Trial. Blood. 2004 Nov 15;104(10):3028-37. PubMed PMID: 15256423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. AU - Hunault,Mathilde, AU - Harousseau,Jean-Luc, AU - Delain,Martine, AU - Truchan-Graczyk,Malgorzata, AU - Cahn,Jean-Yves, AU - Witz,Francis, AU - Lamy,Thierry, AU - Pignon,Bernard, AU - Jouet,Jean-Pierre, AU - Garidi,Reda, AU - Caillot,Denis, AU - Berthou,Christian, AU - Guyotat,Denis, AU - Sadoun,Alain, AU - Sotto,Jean-Jacques, AU - Lioure,Bruno, AU - Casassus,Philippe, AU - Solal-Celigny,Philippe, AU - Stalnikiewicz,Laure, AU - Audhuy,Bruno, AU - Blanchet,Odile, AU - Baranger,Laurence, AU - Béné,Marie-Christine, AU - Ifrah,Norbert, AU - ,, Y1 - 2004/07/15/ PY - 2004/7/17/pubmed PY - 2004/12/24/medline PY - 2004/7/17/entrez SP - 3028 EP - 37 JF - Blood JO - Blood VL - 104 IS - 10 N2 - Various transplantation strategies have been designed to improve the poor prognosis of adult (ages 15 to 60 years) acute lymphoblastic leukemia (ALL). The GOELAL02 trial evaluated the impact of early allogeneic bone marrow transplantation (alloBMT) or delayed unpurged autologous stem cell transplantation (ASCT) for patients who had no human leukocyte antigen (HLA)-matched sibling donor or who were older than 50 years. Inclusion criteria included at least one of the following: age older than 35 years; non-T-ALL; leukocytosis greater than 30 x 10(9)/L; t(9;22), t(4;11), or t(1; 19); or failure to achieve complete remission (CR) after one induction course. Among 198 patients, the median age was 33 years. The CR rate was 80% with vincristine, idarubicine, L-asparaginase, and randomized intravenous injection or oral steroids (P = nonsignificant [ns]). AlloBMT was performed after 2 consolidation courses while ASCT was delayed after 1 additional reinduction. Intensified conditioning regimen before transplantation included etoposide, cyclophosphamide, and total body irradiation (TBI). Median follow-up was 5.1 years. The median overall survival (OS) was 29 months, with a 6-year OS of 41%. On an intent-to-treat analysis for patients younger than 50 years, alloBMT significantly improved the 6-year OS (75% versus 40% after ASCT; P = .0027). Randomized interferon-alpha maintenance had no effect on relapse or survival after ASCT. In conclusion, the outcome of adult ALL is better after early alloBMT than after delayed ASCT. SN - 0006-4971 UR - https://www.unboundmedicine.com/medline/citation/15256423/Better_outcome_of_adult_acute_lymphoblastic_leukemia_after_early_genoidentical_allogeneic_bone_marrow_transplantation__BMT__than_after_late_high_dose_therapy_and_autologous_BMT:_a_GOELAMS_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-4971(20)55855-2 DB - PRIME DP - Unbound Medicine ER -